Cns Historical Financial Ratios
| CNSP Stock | USD 0.12 0.01 7.69% |
Cns Pharmaceuticals is presently reporting on over 85 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 0.0 will help investors to properly organize and evaluate Cns Pharmaceuticals financial condition quickly.
Cns |
About Cns Financial Ratios Analysis
Cns PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cns Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cns financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cns Pharmaceuticals history.
Cns Pharmaceuticals Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Average Inventory
The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.Ev To Free Cash Flow
A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.Most ratios from Cns Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.At this time, Cns Pharmaceuticals' Days Of Payables Outstanding is relatively stable compared to the past year.
Cns Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Cns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cns Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 8.5K | 2.1K | 2.7K | 401.85 | (1.07) | (1.13) | |
| Book Value Per Share | 0.69 | 1.27 | 0.39 | 0.3 | (59.09) | (56.14) | |
| Free Cash Flow Yield | (5.5E-5) | (2.5E-4) | (7.56E-4) | (0.003232) | (2.97) | (2.82) | |
| Operating Cash Flow Per Share | (0.32) | (0.67) | (0.8) | (0.39) | (188.53) | (179.11) | |
| Pb Ratio | 8.5K | 2.1K | 2.7K | 401.85 | (1.07) | (1.13) | |
| Free Cash Flow Per Share | (0.33) | (0.67) | (0.8) | (0.39) | (188.59) | (179.16) | |
| Roic | (0.51) | (0.66) | (2.0) | (1.79) | 4.57 | 4.79 | |
| Net Income Per Share | (0.35) | (0.86) | (0.85) | (0.56) | (251.35) | (238.78) | |
| Cash Per Share | 0.66 | 1.28 | 0.29 | 0.37 | 7.32 | 7.68 | |
| Pocfratio | (18.3K) | (4.0K) | (1.3K) | (309.55) | (0.34) | (0.35) | |
| Interest Coverage | (86.65) | (2.9K) | (1.5K) | (2.2K) | (2.5K) | (2.6K) | |
| Pfcf Ratio | (18.2K) | (4.0K) | (1.3K) | (309.42) | (0.34) | (0.35) | |
| Income Quality | 0.92 | 0.77 | 0.96 | 0.69 | 0.75 | 0.54 | |
| Roe | (0.51) | (0.68) | (2.19) | (1.88) | 4.25 | 3.37 | |
| Ev To Operating Cash Flow | (18.3K) | (4.0K) | (1.3K) | (308.64) | (0.32) | (0.34) | |
| Pe Ratio | (16.8K) | (3.1K) | (1.2K) | (213.97) | (0.25) | (0.27) | |
| Return On Tangible Assets | (0.49) | (0.6) | (1.66) | (1.17) | (11.08) | (10.53) | |
| Ev To Free Cash Flow | (18.2K) | (4.0K) | (1.3K) | (308.51) | (0.32) | (0.34) | |
| Earnings Yield | (6.0E-5) | (3.22E-4) | (8.09E-4) | (0.004674) | (3.96) | (3.76) | |
| Net Debt To E B I T D A | 1.89 | 1.44 | 0.32 | 0.63 | 0.0131 | 0.0125 | |
| Current Ratio | 25.38 | 8.13 | 3.5 | 2.55 | 0.26 | 0.25 | |
| Tangible Book Value Per Share | 0.69 | 1.27 | 0.39 | 0.3 | (59.09) | (56.14) | |
| Graham Number | 2.35 | 4.95 | 2.73 | 1.94 | 578.1 | 607.01 | |
| Shareholders Equity Per Share | 0.69 | 1.27 | 0.39 | 0.3 | (59.09) | (56.14) | |
| Graham Net Net | 0.63 | 1.1 | 0.17 | 0.19 | (74.46) | (70.73) | |
| Interest Debt Per Share | 0.004034 | 0.0402 | 0.0234 | 0.0153 | 4.01 | 4.21 | |
| Enterprise Value Over E B I T D A | (17.0K) | (3.1K) | (1.2K) | (213.6) | (0.24) | (0.25) | |
| Price Earnings Ratio | (16.8K) | (3.1K) | (1.2K) | (213.97) | (0.25) | (0.27) | |
| Price Book Value Ratio | 8.5K | 2.1K | 2.7K | 401.85 | (1.07) | (1.13) | |
| Price Earnings To Growth Ratio | 352.45 | (21.69) | 1.5K | 6.25 | 0.004578 | 0.004349 |
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cns Stock
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Cns Stock
| 0.67 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.41 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.4 | ITCL | Banco Ita Chile | PairCorr |
| 0.39 | KB | KB Financial Group | PairCorr |
| 0.38 | FNMFO | Federal National Mortgage Upward Rally | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.